Unicycive Secures Patent for Kidney Disease Treatment UNI-494, Valid Until 2040
Unicycive Secures Patent for Kidney Disease Treatment UNI-494, Valid Until 2040
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the issuance of U.S. Patent No. 12,036,211 by the United States Patent and Trademark Office (USPTO) for UNI-494.
临床阶段的生物技术公司Unicycive Therapeutics, Inc. (NASDAQ: UNCY)开发针对肾病患者的治疗方案（公司简称“公司”或“Unicycive”），今天宣布美国专利和商标局（USPTO）颁发了U.S.专利号12,036,211，涉及UNI-494。
The patent, valid until 2040, secures protection of a method of treating a disease or a condition selected from acute kidney injury or contrast induced nephropathy by administering the UNI-494 compound. The UNI-494 compound covered in the method of use claims is not limited to a particular salt, dose or type of administration. UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease.
有效期至2040年的专利，确保通过注射UNI-494化合物治疗急性肾损伤或造影剂肾病的方法受到保护。使用权索赔方面涉及的UNI-494化合物不局限于特定的盐、剂量或类型。UNI-494是一种新颖的烟酰胺酯衍生物，是一种选择性的ATP敏感线粒体钾通道激动剂。线粒体功能障碍在急性肾损伤和慢性肾病的进展过程中发挥着关键作用。
